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Abstract
Background: High grade gliomas are one of the most difficult cancers to treat and despite
surgery, radiotherapy and temozolomide-based chemotherapy, the prognosis of glioma patients is
poor. Resistance to temozolomide is the major barrier to effective therapy. Alternative therapeutic
approaches have been shown to be ineffective for the treatment of genetically unselected glioma
patients. Thus, novel therapies are needed. Mitochondria-directed chemotherapy is an emerging
tool to combat cancer, and inner mitochondrial permeability transition (MPT) represents a target
for the development of cytotoxic drugs. A number of agents are able to induce MPT and some of
them target MPT-pore (MPTP) components that are selectively up-regulated in cancer, making
these agents putative cancer cell-specific drugs.
Objective: The aim of this paper is to report a comprehensive analysis of the effects produced by
selected MPT-inducing drugs (Betulinic Acid, Lonidamine, CD437) in a temozolomide-resistant
glioblastoma cell line (ADF cells).
Methods: EGFRvIII expression has been assayed by RT-PCR. EGFR amplification and PTEN deletion
havebeenassayedbydifferential-PCR.Drugseffectoncellviabilityhasbeentestedbycrystalvioletassay.
MPThasbeentestedbyJC1staining.Drugcytostaticeffecthasbeentestedbymitoticindexanalysis.Drug
cytotoxic effect has been tested by calcein AM staining. Apoptosis has been assayed by Hoechst
incorporation and Annexine V binding assay. Authophagy has been tested by acridine orange staining.
Results: We performed a molecular and genetic characterization of ADF cells and demonstrated
that this line does not express the EGFRvIII and does not show EGFR amplification. ADF cells do
not show PTEN mutation but differential PCR data indicate a hemizygous deletion of PTEN gene.
We analyzed the response of ADF cells to Betulinic Acid, Lonidamine, and CD437. Our data
demonstrate that MPT-inducing agents produce concentration-dependent cytostatic and cytotoxic
effects in parallel with MPT induction triggered through MPTP. CD437, Lonidamine and Betulinic
acid trigger apoptosis as principal death modality.
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Open AccessConclusion: The obtained data suggest that these pharmacological agents could be selected as
adjuvant drugs for the treatment of high grade astrocytomas that resist conventional therapies or
that do not show any peculiar genetic alteration that can be targeted by specific drugs.
Background
High grade gliomas, which include anaplastic gliomas
(WHO grade III) and glioblastomas (GBM, WHO grade
IV) are the most common types of primary brain tumor
in adults. The prognosis for patients with this tumor is
very poor, with most of them dying within 1 year after
diagnosis [1]. With the current standard care – which
consists of maximal surgical resection, concurrent radia-
tion therapy and daily temozolomide (TZM), and six
cycles of adjuvant TZM – a median survival time of 14,6
months may be achieved in newly diagnosed GBM
patients [2]. Resistance to TZM treatment, due to the
activation of DNA repair proteins remains a major
barrier to effective therapy [3] and high grade gliomas
almost always recur. Salvage therapies at recurrence
produce minimal improvement in 6-month progression-
free survival [4]. Some alterations that govern GBMs has
been outlined, the most frequent among them are LOH
10q, Phosphatase and Tensin homolog (PTEN) muta-
tion/deletion and Epidermal Growth Factor Receptor
(EGFR) amplification/overexpression [5]. EGFR has been
found overexpressed in a number of GBMs [6] and has
been used as a prime target for therapeutic intervention
with inhibitory agents. However, several studies that
have been conducted to evaluate the effectiveness of the
EGFR inhibitors have shown that their use in unselected
patients with malignant gliomas remains unproven
[7-9]. Similarly, the use of inhibitors of other transduc-
tion pathways have been shown to be ineffective for
the treatment of unselected patients suggesting that
the inhibition of a specific pathway may result in the
activation of a compensatory pathway that allows the
tumour to survive. For these reasons novel therapeutic
approaches are strongly needed.
Mitochondria-directed chemotherapy is emerging as a
promising tool to combat apoptosis-resistant cancer cell
proliferation [10-12]. Mitochondria are the cell energy
producers and are essential for maintaining cell life;
however, they also play a key role in cell death when
their membranes become permeabilized. Mitochondrial
membrane permeabilization includes either outer mem-
brane permeabilization or inner membrane permeabili-
zation (IMP). IMP produces the so called mitochondrial
permeability transition (MPT) that compromises the
normal integrity of the mitochondrial inner membrane
which becomes freely permeable to protons leading to
uncoupling oxidative phosphorylation [13]. The most
accredited theory to explain the MPT is the opening of a
multiprotein complex, the mitochondrial permeability
transition pore (MPTP), located at the contact site
between the inner and outer mitochondrial membranes.
The composition of the MPTP is still unknown and
results from the association of several proteins. Among
them, the adenine nucleotide translocator (ANT), the
voltage-dependent ion channel (VDAC), the translocator
protein (TSPO), the hexokinase II (HKII) and ciclophy-
line D (CyP-D) are classically described [14].
Like many anti-cancer drugs, the effects of MPT-inducing
agents are felt systemwide but fall most heavily upon
cancer cells that present a switch to a predominant
glycolitic metabolism which renders the mitochondrial
transmembrane potential more instable. Moreover, a
number of these agents induce MPT targeting MPTP
components that are selectively up-regulated in cancer
cells, such as the TSPO and ANT proteins [15-18], thus
reinforcing the cancer selective action of the therapy.
Agents reported to induce MPT targeting the MPTP, are
able to induce cell death in several cells and some of
them have also been reported to exert a mitochondria-
mediated cytotoxic effect on glioma cells [19-23].
However, the activity of these compounds, as well as
their mechanisms of action, have not been yet comple-
tely elucidated in high grade astrocytoma. The aim of
this paper is to report a comprehensive analysis of the
effects produced by a selected group of putative MPTP-
targeting drugs (Betulinic Acid, Lonidamine, CD437, see
[24] for a review) on a TZM-resistant GBM (IV WHO
grade) cell line (ADF cells) that did not show EGFR
amplification/overexpression and that has a hemizygous
deletion of the PTEN gene.
Betulinic acid (BA), a natural product derived from the
bark of the white birch tree [25], has been demonstrated
to potently inhibit the growth of neuroectodermal
tumors, such as neuroblastoma, medulloblastoma, and
Ewing sarcoma cell lines [26] as well as several human
carcinoma [27]. Although the protein target of BA is still
unknown its effects on mitochondrial transmembrane
potential are blocked by the MPTP inhibitor bongkrekic
acid [22]. Lonidamine (LND) has been shown to induce
apoptosis in drug-resistant cells [23] reducing aerobic
glycolytic activity through the inhibition of mitochond-
rially-bound hexokinase (HK) which is present in large
amounts in malignant cells [28, 29]. This inhibition is
probably operated through the interaction with the
MPTP pore component ANT [30]. CD437 displays
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treatment of a number of premalignant and malignant
conditions [31]. The mechanism of action of CD437 is
still poorly understood and it is probable that this drug
acts on different cellular targets [32, 33]. In vitro studies
suggested that one of those targets is the ANT protein
[30].
The data described in this paper will furnish information
about the potential use of MPT-inducing agents for the
treatment of high grade astrocytoma that resist conven-
tional therapies or that do not show peculiar genetic
alteration that can be targeted by specific drugs.
Methods
Drugs
BA (855057, Sigma Aldrich, St. Louis, MO), LND (L4900,
Sigma Aldrich, St. Louis, MO), CD437 (C5865, Sigma
Aldrich, St. Louis, MO), TZM (T2577, Sigma Aldrich, St.
Louis, MO), Ciclosporin A (CsA, 30024, Sigma Aldrich, St.
Louis, MO), CCCP (C2759, Sigma Aldrich, St. Louis, MO)
have been purchased from SIGMA Aldrich. 20 mg/ml, 200
mM, 100 mM, 100 mM, 10 mM, stock solutions have been
prepared in DMSO for BA, LND, TZM, CsA, and CD437
respectively. A 50 mM stock solution was prepared in
ethanol for CCCP.
Cell cultures, tumor and normal brain tissues
Human ADF GBM cell line (obtained from a WHO grade
IV human GBM [34]), were maintained in standard
culture conditions (37°C, 95% humidity, 5% CO2)i n
RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS), 2 mM L-glutamine, 100 U/mL 7
penicillin and 100 μg/mL streptomycin. Two normal
brain tissue samples and one WHO grade IV GBM
sample were obtained from patients enrolled in a
clinical-genetic protocol at Neurosurgery Unit of Livorno
Hospital after the approval of the ethics review commit-
tee of Livorno City (SCS 2008-0019).
Analysis of the expression of the EGFRvIII isoform
EGFR amplicons are often mutated and variant 3
(EGFRvIII) with deletion of exons 2 to 7 is the most
frequent type. To analyze the presence of these variant, 1
μg of total RNA was retrotranscribed and amplified using
the following primers:
Forward: 5'-GGGCTCTGGAGGAAAAGAAA-3'
Reverse: 5'-AGGCCCTTCGCACTTCTTAC-3'
that span from exon 1 to exon 8 [35] at the following
amplification conditions: 2 minutes of initial denatura-
tion at 95°C; 30 cycles including 95°C for 30 seconds,
55°C for 45 seconds and 72°C for 1 minute and 30
seconds; 5 minutes of final extention at 72°C.
RNA obtained from human normal brain tissues and
from a WHO grade IV GBM known to express the EGFR
variant 3 (Lena et al., manuscript in preparation) were
also amplified as negative and positive controls
respectively.
Differential PCR
ADF cells, normal brain tissues and a grade IV glioma
known to have EGFR amplicons and a hemizygous
deletion of PTEN (Lena et al., manuscript in preparation)
were screened for EGFR amplification and homozygous
or hemizygous deletion of PTEN by differential PCR
using genomic primers for PTEN exon 9 (forward
5'-AAACAGTAGAGGAGCCGTCA-3' and reverse
5'-GACTTTTGTAATTTGTGTATGCT-3') or EGFR exon 22
(forward 5'-CATCTGCCTCACCTCCACC-3' and reverse
5'-GCACACACCAGTTGAGCAG-3') together with pri-
mers for the internal allele dosage standard GAPDH
gene from chromosome 12p (forward 5'-CCATCACTGC-
CACCCAGAA-3' and reverse 5'-TGCCAGT-
GAGCTTCCCGTT-3'). Differential PCR was performed
using the Go-Taq PCR Kit (Promega, Madison, WI)
starting from 50 ng of genomic DNA. To avoid unequal
amplification efficiency of genomic PTEN or EGFR and
of the internal standard GAPDH, different PCR condi-
tions have been tested in brain tissue control samples to
obtain amplification bands of equal intensity. According
to this analysis, the amplification conditions were as
follows:
For PTEN amplification: 95°C for two minutes, 30 cycles
including 95°C for 30 seconds, 57°C for 45 seconds,
72°C for 30 seconds.
For EGFR amplification: 95°C for two minutes, 32 cycles
including 95°C for 30 seconds, 55°C for 45 seconds,
72°C for 30 seconds.
For GAPDH amplification: 95°C for five minutes, 32
cycles including 95°C for 30 seconds, 53°C for 45
seconds, 72°C for 30 seconds.
The optimal number of cycles was established according
to a stringent calibration process determining the log-
linear phase of amplification for each gene.
After electrophoresis of the amplified products, each
band was quantified using the ImageJ software [36] and
the EGFR/GAPDH or PTEN/GAPDH ratio has been
calculated. An EGFR/GAPDH ratio ≥ 2 was considered
indicative of genomic amplification. A PTEN/GAPDH
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hemizygous or homozygous deletion respectively.
PTEN mutation analysis
PTEN full length cDNA was amplified from ADF total
RNA using the following primers:
Forward: 5'-ATGACAGCCATCATCAAAGAG-3'
Reverse: 5'-GACTTTTGTAATTTGTGTATGCT-3'
The amplification product was sequenced by automated
fluorescent cycle sequencing (ABI).
Karyological analysis
Chromosome preparations were made according to
standard protocols. Human ADF cells were incubated
with colchicine (0,05 μg/ml) for 3 h at 37°C. Cells, were
harvested by trypsin, treated with hypotonic solution
(0,05 M KCl) for 10 min at 37°C, and then fixed with
Acetic Acid/Ethanol (1:3). After standard preparation,
slides were stained with Giemsa (Carlo Erba). 100
metaphases were scored in three different slides to assess
the chromosome number and aberration.
Crystal violet assay
100000 ADF GBM cells were plated in 24 well plates. The
following day the growth medium was replaced with
fresh medium containing the drug at the final desired
concentration and cells were left to grow for additional
24 hours. Cells were then washed twice with pre-warmed
PBS and fixed in absolute cold methanol for 10 minutes
at minus 20°. After two washes with room temperature
PBS, cells remaining on the well plate were stained for
ten minutes with a crystal violet solution (0.5% crystal
violet, 20% methanol). After removal of the crystal violet
solution, the plates were washed three times by immer-
sion in a beaker filled with tap water. Plates were left to
dry at 37° and 0.6 ml of crystal violet destaining
solution (50% Ethanol, 0.1 M Sodium Citrate, pH 4.2)
were then added to each well. Optical density was then
measured reading the absorbance at 540 nm. Three wells
for each drug concentration were measured; absorbance
values were blank subtracted using as blank the optical
density of wells containing only the growth medium.
The percentage of the organic solvent, in which each
drug was dissolved, never exceeded 1% (v/v) in the
samples. We verified that this amount did not affect cell
viability. The Inhibition Concentration (IC50, the
concentration of drug where 50% of cells die) for each
compound was calculated by a sigmoidal dose-response
curve, using the GraphPad Prism 4 program. To assess
the specificity of the drug cyotoxic effect through the
MPTP, ADF cells were first treated for 30 minutes with
the MPTP-blocker CsA at 1 μM final concentration. After
removal of the MPTP-blocker a new medium containing
the MPT-inducing drugs at the desired concentration was
a d d e dt ot h ec e l l s .
Mitotic index
30000 ADF cells were plated in 24 well plates. The
following day, cells were treated with drugs at the
selected concentration and after additional 5 or 24
hours, adherent cells were detached, collected by
centrifugation and resuspended in 40 μl of a glycerol,
acetic acid, PBS (1:1:13) solution containing 5 μg/ml of
the bis-benzimide Hoechst 33342 (Invitrogen, H21492,
C a r l s b a d ,C A ) .C e l l sw e re treated with 0.05 μg/ml
colchicine for 3 hours before collection. Two 5 μl
aliquots of cell suspension for each sample were spotted
on a glass slide and allowed to dry. The number of
mitotic figures was counted under the fluorescence
microscope. Two 10 μl aliquots for each sample were
used to count the number of total cells with a
hemocytometer. For each treatment, the mitotic index
(mitotic figures/total cells) was calculated in 3 replicate
wells. Two independent experiments were performed. To
assess the specificity of the drug cytostatic effect through
the MPTP, ADF cells were first treated for 30 minutes
with the MPTP-blocker CsA at 1 μM final concentration.
After removal of the MPTP-blocker a new medium
containing the MPT-inducing drugs at the desired
c o n c e n t r a t i o nw a sa d d e dt ot h ec e l l s .
Evaluation of mitochondrial potential by (JC1)
staining assay
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolyl-
carbocyanine iodide (JC1; Invitrogen, T3168, Carlsbad,
CA) is a cationic dye that exhibits potential-dependent
accumulation in mitochondria, indicated by a fluores-
cence emission shift from green (~525 nm) to red (~590
nm). Consequently, mitochondrial depolarization is
indicated by a decrease in the red/green fluorescence
intensity ratio and can be quantified by using both flow
cytometry or fluorescence microscopy [37]. To evaluate
the mitochondrial depolarization induced by drug
treatment, we plated 10000 ADF cells in 96 well plates.
The following day cells were stained for 10 minutes in
medium containing JC-1 at the final concentration of 50
μg/ml. After removal of JC-1, a new medium containing
the drug, at the desired final concentration, was added to
the cells. 3, 6 and 24 hours after the treatment pictures
were taken under an Axiovert fluorescent microscope
(Zeiss) using the filter set 10, 488010-0000 (Zeiss)
(excitation 450–490: emission 515–565). Pictures were
then split in the RGB channels (red and green) and
analyzed by using the program ImageJ [36]. The ΔΨ
Inihibition Concentration (ΔΨ IC50, the concentration
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using the GraphPad Prism 4 program. To assess the
specificity of drug-induced depolarization through the
MPTP, JC1-loaded ADF cells were first treated for 30
minutes with the MPTP-blocker CsA at 1 μMf i n a l
concentration. After removal of the MPTP-blocker a new
medium containing the MPT-inducing drugs, at the
desired concentration was added to the cells.
Assessment of cell death modality
- Hoechst uptake, propidium iodide incorporation and
acetomethoxy derivate of calcein staining assays
20000 cells were plated in 96 well plates. The following
day, cells were treated with drugs at the selected
concentration and after additional 24 or 48 hours were
stained with 5 μg/ml Hoechst 33342, 2 μg/ml Propidium
iodide (PI, Sigma-Aldrich, 81845, St. Louis, MO) and 1
μM acetomethoxy derivate of calcein (calcein AM,
Sigma-Aldrich, C1359, St. Louis, MO) for 10 minutes
at 37°C. After staining, both floating and adherent cells
were collected and analyzed using a hemocytometer
under a fluorescence microscope. Cells that, indepen-
dently from calcein staining, avidly incorporated the
Hoechst dye and showed typical morphological features
such as chromatin condensation and margination, were
considered apoptotic cells according to [38]. Frequently,
late apoptotic cells were also PI positive due to a
secondary necrotic process that generally takes place in
cultured apoptotic cells. The ratio between apoptotic
cells and total cells (A/T ratio) was calculated. Cells that
were calcein negative and PI positive and that did not
show the typical nuclear apoptotic alterations were
considered necrotic cells. The ratio between necrotic
and total cells (N/T ratio) was calculated. Cells that were
hoechst 33342 and PI negative and that showed a strong
calcein staining were considered live cells. The ratio
between live and total cells (L/T ratio) was calculated.
The A/T, N/T and L/T ratios were evaluated in three wells
for each experimental condition; cells detached from
each well were counted in duplicate. To assess the
specificity of the drug apoptotic effect through the MPTP,
ADF cells were first treated for 30 minutes with the
MPTP-blocker CsA at 1 μM final concentration. After
removal of the MPTP-blocker new medium containing
the MPT-inducing drugs at the desired concentration,
was added to the cells.
- Annexin V binding assay
Based on the phenomenon that phospholipids (PS) are
exposed during apoptosis and on the ability of annexin V
to bind to PS with high affinity, we used annexin V to
detect apoptosis. 15000 cells were plated in 96 well
plates. The following day, cells were treated with the
drugs at the desired concentration and after an
additional 24 hours, we analyzed the annexin V-
positive/PI-negative cells using the Annexin V-FITC
Fluorescence Microscopy Kit (BD Biosciences, Franklin
Lakes, NJ) following manufacturer's instructions.
- Detection of acidic vesicular organelles (AVOs)
As a marker of autophagy, the appearance and volume
AVOs was visualized by acridine orange staining [39].
Briefly, 20000 ADF cells were seeded in 96 well plates.
The following day, cells were treated with drugs at the
selected concentration and after 6, 24 or 48 hours were
incubated in serum-free medium containing 1 μg/ml
acridine orange for 15 minutes at 37°C. The acridine
orange was removed and fluorescent micrographs were
taken using an inverted fluorescent microscope. The
cytoplasm and nucleus of the stained cells fluoresced
bright green, whereas the acidic autophagic vacuoles
fluoresced bright orange. In order to carry out a
specificity control cells were treated with 200 nM
bafilomycin A1 for 30 minutes before the addition of
acridine orange to inhibit the acidification of autophagic
vacuoles.
Results
Genetic characterization of the human glioma ADF cells
In order to characterize the cellular model system to test
the selected MPT-inducing agents, some karyological and
genetic aspects of ADF cells (especially the the most
frequently described genetic aberration in gliomas) were
analyzed. Karyological studies revealed that ADF cells are
aneuploid with a mean number of chromosomes for
metaphase of 58 ± 5. Moreover several chromosomal
abnormalities such as double minutes and single or
double chromatid gaps or breaks were detected. Inter-
estingly, about 50% of ADF cells showed a single minute
frequently associated with a medium-size sub-meta-
centric chromosome (data not shown).
As demonstrated by EGFR transcript amplification, by
RT-PCR assay, ADF cells and normal brain tissue did not
express the EGFRvIII variant that is visible in a grade IV
glioblastoma sample used as positive control (Fig 1).
Accordingly, ADF cells did not show EGFR genomic
amplification as demonstrated by densitometry analysis
of the differential PCR assay. On the contrary an EGFR/
GAPDH ratio ≥ 2 was obtained in a grade IV glioblas-
toma sample, known to have EGFR amplicons, that we
used as positive control (Fig. 2).
Sequence analysis of PTEN cDNA, isolated from ADF
cells, did not reveal mutations. However, differential
PCR analysis performed using PTEN exon 9 directed
primers, revealed a PTEN/GAPDH ratio of 0.3 indicating
an hemizygous deletion of PTEN. As expected a PTEN/
Journal of Translational Medicine 2009, 7:13 http://www.translational-medicine.com/content/7/1/13
Page 5 of 13
(page number not for citation purposes)GAPDH ratio close to 1 was found in normal human
brain tissues and a 0.3 ratio was found in a grade IV GBM
sample, known to have PTEN hemizygous deletion that
we used as a positive control (Fig. 2).
MPT-inducing drugs affect TZM-resistant glioma cell
viability and dissipate the mitochondrial transmembrane
potential through the modulation of MPTP opening
Crystal violet staining assay was performed to test the
reduction in cell viability produced by TZM and by the
selected MPTP-targeting drugs on ADF glioma cells. As
s h o w ni nF i g u r e3 ,A D Fc e l l sw e r eu n a f f e c t e db yT Z M ,2 4
hours after treatment. On the contrary, LND, CD437 and
BAaffected ADF viability in a dose dependent manner, 24
hours after treatment. IC50 values were 13 ± 2; 6 ± 3 and
240 ± 10 for BA, CD437 and LND respectively. CCCP was
used as a positive control. The treatment with the well
known MPTP blocker CsA did not produce a reduction in
cell viability at the concentration of 1 μM at which it will
be used in the following experiments (see below).
To test whether the reduction of viability produced by LND,
CD437, and BA was the result of MPT induction, the ΔΨ
dissipation as a consequence of a 6 or 24 hour-long
treatment with the drugs was analyzed. As shown in Figure
4,allthe selecteddrugswereable toproducea sustainedΔΨ
dissipation 24 hours after treatment. ΔΨ IC50 are also
reported in Figure 4. As expected a 24 hour-long treatment
withtheMPTP-blockerCsAdidnotproduceΔΨdissipation.
ΔΨ dissipation was also evaluated 6 hours after the
treatment using the highest concentration tested in the
24hour-longexposure.OnlyCD437wasabletoproducean
early significant ΔΨ dissipation. A 3 h treatment with the
uncoupling agent CCCP was used as positive control. To
determine whether the drug-induced MPT was mediated by
the opening of MPTP a pre-treatment with the MPTP-
blocker CsA was performed prior to the treatment with the
selected drugs. As shown in Figure 5, CsA treatment alone
did not show any effect on ΔΨ, while CsA pretreatment
totally abolished the ΔΨ dissipation effect triggered by
CCCP, LND, CD437 and BA.
With the aim of understanding whether MPT induction
through the MPTP plays a leading role in the reduction
in cell viability produced by the selected drugs, the
capability of CsA to protect ADF cells from the effects of
MPT-inducing drugs on cell viability was analyzed. As
shown in Figure 6, the effect of CD437 on cell viability,
Figure 1
Analysis of EGFR variant III expression.E G F R v I I Iw a s
not expressed in ADF cells. Arrow indicates EGFRvIII (128
bp) amplification band. NB1, normal brain tissue sample 1;
NB2, normal brain tissue sample 2; GBIV, WHO grade IV
glioblastoma; MWL, molecular weight ladder.
Figure 2
Differential PCR. ADF cells did not show EGFR
amplification and have a hemizygous deletion of the
chromosome 10q region containing the PTEN locus.
Amplification bands of representative experiments are
depicted for each gene in the analized samples. NB1, normal
b r a i nt i s s u es a m p l e1 ;N B 2 ,n o r m a lb r a i nt i s s u es a m p l e2 ;
GBIV, WHO grade IV glioblastoma; E/G, mean ratio of
densitometry values of EGFR and GAPDH amplification
bands. P/G, mean ratio of densitometry values of PTEN and
GAPDH amplification bands.
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reducedwhenapre-treatmentof30minuteswasperformed
with the MPTP-blocker CsA at 1 μM, a concentration that
does not alter cell viability after 24 hours of continuous
treatment (Fig. 3). On the contrary, the effects produced by
LND and BA treatment at the IC50 dose were not
significantly affected by the CsA pre-treatment.
MPT-inducing drugs act as both cytostatic and
cytotoxic compounds on ADF cells
Mitotic indexes have been calculated to evaluate the
cytostatic effect produced on ADF cell proliferation by
treatment with the selected drugs at the IC50 dose. As
shown in Figure 7A, BA and LND produced a significant
reduction of the mitosis number, 24 hours after the
treatment. Interestingly, CD437 produced an early
antiproliferative effect 5 hours after the treatment that
resulted in the complete absence of mitosis, 24 hours
after treatment. Reduction of mitoses produced by
CD437 proved insensitive to CsA pre-treatment.
Calcein AM staining was used to evaluate the cytotoxic
effect produced by the selected drugs at the IC50 dose.
Calcein AM is transported through the cellular mem-
brane into live cells, where intracellular esterases remove
the acetomethoxy group allowing the molecule to bind
calcium and to produce a strong green fluorescence. As
dead cells lack active esterases, only live cells are labeled.
As shown in figure 7B the number of live calcein positive
cells was significantly reduced 24 and 48 hours after
treatment with the selected drugs at the IC50 dose.
MPT-inducing drug treatment leads to apoptosis
Owing to changes in membrane permeability, early
apoptotic cells show an increased uptake of Hoechst
33342 compared with live cells [38]. This feature was
used to assay the ability of LND, BA, and CD437 to
produce apoptotic cell death. In our analysis we
considered as apoptotic cells those cells that showed
strong Hoechst 33342 staining and typical apoptotic
nuclear morphology (Fig. 8A). As indicated in Figure 8B
Figure 3
Effect of CD437, LND, BA, TZM, CCCP and CsA
treatment on ADF cell viability as assessed by crystal
violet assay. ADF cells are resistant to TZM and their
viability is affected by CD437, LND and BA. (A) The Graph
indicates the dose dependent effect on cell viability measured
24 hours after the treatment with TZM. (B) Sigmoidal dose-
response curve of the effect on cell viability measured 24
hours after the treatment with LND, CD437, BA, CCCP and
CsA. Each value has been normalized versus the vehicle
treated control to which an arbitrary value of 100% has been
assigned. Each point is the mean of two independent
experiments performed in triplicate.
Figure 4
Effect of CD437, LND, BA, CCCP and CsA
treatment on mitochondrial transmembrane
potential as assessed by JC1 staining.C D 4 3 7 ,L N Da n d
BA treatment produces a dose dependent ΔΨ dissipation.
(A) Vehicle treated cells stained with JC1. (B) ADF cells
treated with BA at the ΔΨ IC50 dose and stained with JC1.
Graphs indicate the dose dependent ΔΨ dissipation
expressed as Red/green (R/G) fluorescence ratio. Each value
has been normalized versus the R/G ratio of the vehicle
treated control to which an arbitrary value of 100% has been
assigned. Each point is the mean of two independent
experiments performed in triplicate.
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(page number not for citation purposes)in CD437, BA, and LND treated cells a higher number of
Hoechst positive nuclei was observable with respect to
vehicle treated controls 24 and 48 hours after the
treatment at the IIC50 dose. Interestingly, the CsA
pretreatment reduced to a half the number of apoptotic
cells counted after CD347 treatment. In this assay, we
discriminated between dead (necrotic) and apoptotic
cells by adding the membrane impermeable DNA dye PI
s i m u l t a n e o u s l yt ot h ec e l l s .T h o s ec e l l st h a tw e r eP I
positive, calcein AM negative and that showed a normal
Figure 5
Effect of CsA pre-treatment on ΔΨ dissipation
produced by CCCP, CD437, LND and BA treatment.
CsA treatment prevents CD437-, BA- and LND-induced ΔΨ
dissipation. Each value has been normalized versus the R/G
ratio of the vehicle treated control without CsA to which an
arbitrary value of 100% as been assigned. R/G ratios have
been calculated 24 hours after treatment at the IC50 dose.
Each bar is the mean of two experiments performed in
triplicate. The R/G ratios of drug treated samples normalized
versus the R/G ratio of the vehicle treated control were
compared with the R/G ratio of CsA+drug treated samples
normalized versus the R/G ratio of the CsA+vehicle treated
control using the unpaired t-test. *P <0 . 0 5 ;* * P < 0.01; ***P
< 0.001.
Figure 6
Effect of CsA pre-treatment on viability reduction
produced by CD437, LND and BA treatment.C s A
treatment protects ADF cells from CD437 effects and has no
influence on the reduction in cell viability produced by BA
and LND. Each value has been normalized versus the vehicle
treated control to which an arbitrary value of 100% as been
assigned. Cell viability has been measured by crystal violet
assay 24 hours after the treatment at the IC50 dose. Each bar
is the mean of two experiments performed in triplicate. The
absorbance values of the drug treated samples were
compared with those of the vehicle treated control using the
unpaired t-test. **P <0 . 0 1 .
Figure 7
Cytostatic and cytotoxic effects of CD437, LND and
BA treatment on ADF cells.C D 4 3 7 ,B Aa n dL N De x e r t
both cytostatic and cytotoxic effects on ADF cells. (A)
Mitotic index analysis. Each value has been normalized versus
the respective vehicle treated control to which an arbitrary
value of 100% as been assigned. Each point is the mean of
two independent experiments performed in triplicate. The
mitotic indexes of drug treated samples were compared with
those of the vehicle treated controls using the unpaired t-test
*P <0 . 0 5 ;* * P < 0.01. (B) Calcein AM staining assay. Each bar
indicates the percentage of live and death cells and is the
mean of two experiments performed in triplicate. The
number of live cells counted in the drug treated samples was
compared to that of the vehicle treated controls using the
unpaired t-test. *P <0 . 0 5 ;* * P < 0.01; ***P < 0.001.
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(page number not for citation purposes)nuclear morphology we considered to be necrotic. A few
necrotic cells were counted in BA and LND treated cells
24 and 48 hours after the treatment (data not shown).
To confirm the ability of the selected drugs to induce
apoptotic cell death, we also evaluated the PS externa-
lization through Annexin V binding 24 hours after
treatment with the selected drugs at the IC50 dose. All
the analyzed drugs showed a significant increase in
Annexin V reactivity with respect to vehicle treated
controls (Fig. 8C). In addition, the majority of Annexin V
positive cells did not show PI staining.
The ability of the selected drugs to induce autophagic cell
death was also analyzed. Autophagy is characterized by the
development of acidic vesicular organelles (AVO), which is
measured by vital staining of acridine orange. AVO positive
cells were not detectable 6, 24 and 48 hours after the
treatment with CD437 and LND either at the IC50 or
higher doses. However, several AVO-positive cells were
detectable 6, 24 and 48 hours after treatment with BA
(Fig. 9). The number and brightness of BA induced AVO
were not reduced in the presence of CsA (Fig. 9).
Discussion
The aim of this paper is to propose MPT inducing drugs
as adjuvants in chemotherapy protocols for the treat-
ment of high grade astrocytoma.
Several ground-breaking therapeutic approaches, based
on inhibitors of tumor-specific hyperactivated transduc-
tion pathways, are emerging for glioma treatment.
However, the outcome of this kind of treatment is
strictly dependent upon the gene expression/protein
activation profile of each malignant glioma. Thus, these
inhibitors are not recommended for unselected malig-
nant glioma patients leaving a large part of them without
an alternative to TZM.
Gliomas are a very diverse and complex group of
neoplasms with a pronounced genetic heterogeneity.
Thus the in vitro analysis of the effects produced by a
putative chemotherapeutic agent should be analyzed
B
C
A
Figure 8
Assessment of apoptotic cell death. CD437, BA and
LND induce apoptosis of ADF cells. (A) An apoptotic
nucleus. (B) Percentage of apoptotic cells (assuming as 100%
the number of total cells) in drug treated samples and in
vehicle treated controls 24 and 48 hours after treatment.
The number of apoptotic cells counted in the drug treated
samples was compared with that of the vehicle treated
controls using the unpaired t-test. *P <0 . 0 5 ;* * P < 0.001.
(C)ArepresentativeexampleofannexinVbindingassay.Several
cells show annexine V cross reactivity on their membranes in
CD437, BA and LND treated samples. In the merged panel
Annexin V and PI signals appear purple and cyan respectively.
Figure 9
Assessment of AVOs formation by acridine orange
staining. BA induces autophagy in ADF cells. A
representative example of acridine orange stained cells.
Bright orange granules are evident in BA and CsA+BA
treated cells. As specificity control, cells treated with 200 nM
bafilomycin A1 (BAF) for 30 minutes before the addition of
acridine orange do not show AVOs formation.
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the model cell line fit into and, consequently, translate in
vivo the obtained data in accordance with the genetic
mutations that govern GBM. To this aim we characterized
ADF cells in accordance with the most frequent genetic
aberrations that are documented in glioblastoma. ADF cells
show a high kariologycal variability with several chromo-
somal aberrations including recurrent minute chromo-
somes that are frequently detected in tumor cells and are
indicative of gene amplification. ADF cells did not show
EGFR amplification as demonstrated by both the absence
of the EGFR variant III and the low EGFR/GAPDH ratio
obtained in the differential PCR assay. This feature excludes
ADF cells as targets for the inhibitors of EGFR. Although
ADF express a wild-type form of PTEN, differential PCR
assays indicated a hemizygous deletion of the chromo-
some 10q region containing the PTEN locus suggesting a
reduced PTEN expression leading to a strongly deregulated
cell growth. Interestingly, we demonstrated that ADF cells
are unaffected by high TZM concentrations, suggesting that
they have developed TZM resistance as often happens in
vivo at early recurrence of glioblastoma tumors. This data
are consistent with a previous report that demonstrated
that ADF cells are resistant to carmustine treatment [40].
For these reasons, ADF cells represent the elective model
system of high grade astrocytoma cells, untreatable with
standard and trial therapies, where to test the effects of
mitochondria-damaging agents.
Here, we firstly tested the ability of BA, LND and CD437
to affect ADF cell viability in a dose dependent manner
24 hours after treatment by using the crystal violet assay.
All the tested compounds were able to reduce cell
viability with respect to vehicle treated controls. The
ability of BA to reduce cell viability is particularly
interesting since, for glial tumors, previously published
results are conflicting. In fact, although this drug was
originally claimed to induce apoptosis in several cancer
cell lines [27], very high concentrations of BA (as high as
50 μg/ml) were needed to detect signs of apoptosis in
quite a few malignant glioma cell lines [41]. In this paper
we demonstrate that ADF cells are highly affected by BA
treatment and that a 24 hour treatment with 12.5 μg/ml
is able to produce a 50% reduction in cell viability. This
finding suggests that still unknown genetic features make
different glioma cell lines differently vulnerable to BA
treatment.
We also demonstrated that LND, BA and CD437 are able
to induce a potent ΔΨ d i s s i p a t i o nm e d i a t e db yM P T Pa s
demonstrated by the ability of CsA to totally abolish
LND-, BA- and CD437-mediated MPT induction. Among
the selected compounds, CD437 proved more efficient
in the ΔΨ dissipation being able to produce a very early
mitochondrial damage. Moreover, the effects triggered
by this compound on cell viability were significantly
reduced as a consequence of a CsA pre-treatment,
indicating that ΔΨ dissipation is a leading event for
cell viability reduction produced by CD437. CD437
mechanism of action is still poorly understood and this
finding suggests that the primary and early mitochon-
drial damage could be responsible for the other effects
described for this drug [33, 41-44]. On the contrary, ΔΨ
dissipation is probably only a concurrent event in cell
viability reduction produced by LND and BA. This
hypothesis is also confirmed by the discrepancy between
the very low LND and BA dose necessary to produce ΔΨ
dissipation and the highest dose of these drugs useful to
induce viability reduction. Moreover, this finding is
consistent with the role proposed for LND that being
thought to inhibit glycolysis by inactivation of the
mitochondrially bound hexokinase, it could affect cell
viability inhibiting the exclusive glycolitic cancer cells
metabolism [45].
Crystal violet assay allows us to evaluate the number of
cells that remain adherent to the well plate after the
treatment. However, this assay does not give any
information about the mechanism responsible for the
reduction in viability. Several hypotheses could be
therefore assumed, one of which is that the compounds
could act as cytotoxic and/or cytostatic agents. To test a
hypothetical cytostatic activity of the selected com-
pounds we evaluated the mitotic index of cells treated
at the IC50 dose 5 and 24 hours after treatment. For LND
and BA a reduction in the mitotic index could be
observed only 24 hours after the treatment, while CD437
proved very active in inhibiting cell proliferation, and an
early reduction in the number of mitoses can be
observed 5 hours after the treatment and no mitosis
could be counted 20 hours later. The antiproliferative
effect of CD437 was insensitive to CsA pre-treatment
indicating that CD437 induced cell-cycle arrest is not
mediated by MPTP.
We also evaluated the cytotoxic activity of the selected
drugs. Firstly we evaluated the number of live and death
cells using as samples both adherent and floating ADF
cells 24 and 48 hours after the treatment at IC50 dose.
For all the compounds a significantly higher number of
death cells could be detected in comparison with the
vehicle treated controls 24 and 48 hours after the
treatment. In particular, a very high number of dead
cells were observed in BA treated samples starting from
24 hours after the treatment while a noticeable high
number of dead cells could be observed in CD437
treated samples only 48 hours after treatment. Taken
together the data obtained from both the calcein AM
staining and mitotic index, allow us to suggest that LND
and BA have a primary cytotoxic effect and that the
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after the treatment could be a consequence of cell stress.
On the contrary, CD437 causes an early proliferation
arrest that may account for a consistent part of the
reduction in cell viability monitored by crystal violet
assay. Only in a second phase, do cell cycle arrested cells
undergo a death process.
All the tested compounds produce their citotoxic effect
inducing apoptotic cell death as demonstrated by
Hoechst uptake and annexin V binding assays. Only a
few necrotic cells were detected in LND and BA treated
cells excluding necrosis as a relevant death pathway
induced by these compounds. The number of apoptotic
cells in CD437 treated samples was only slightly higher
than that counted in vehicle treated samples 24 hours
after the treatment, confirming that the primary effect
produced by CD437 is the cell cycle arrest. Later on, a
higher and significant number of apoptotic cells was
observed in CD437 treated samples with respect to
controls. CsA pre-treatment strongly reduced the number
of apoptosis in CD437 treated samples indicating that
the cell cycle-arrested cells produced by the treatment
with this drug underwent apoptotic cell death primarily
through MPT induction.
We also assayed the ability of the selected compounds to
produce autophagic cell death by using the acridine
orange staining. CD437 and LND were not able to
induce AVOs formation in the cell cytoplasm. On the
contrary, BA was able to induce AVOs formation very
early after treatment. BA capability to induce AVOs was
not inhibited by CsA pre-treatment suggesting that BA
can also produce a cytotoxic effect through a MPTP-
independent mechanism thus explaining the CsA insen-
sitive cell viability reduction produced by this drug. The
coexistence of different death mechanisms in BA treated
cells could also account for the discrepancy between the
extraordinarily high number of dead cells observed with
calcein AM staining and the relatively lower number of
apoptotic cells counted by Hoechst incorporation assay.
It can be expected that the treatment with compounds
that lead to ΔΨ dissipation produces a stereotyped cell
response. Actually, data obtained in this paper confirm
several previous reports that describe different cell
responses to the administration of MPT-inducing
drugs. To explain this diversity it has to be taken into
account that the different compounds produce MPT
through different pathways by acting on still not well
defined mitochondrial targets. As a consequence, the
timing and intensity of MPT are extremely variable. This
feature, together with the possible action of the MPT-
inducing agents on other cellular targets could explain
the variable cell response.
Conclusion
In conclusion, mitochondrial damaging agents have the
potential to be included in therapeutic protocols as
adjuvant to radiotherapy or TZM treatment. The poten-
tial value of LND has been previously evaluated for the
treatment of malignant gliomas [46, 47]. In particular, a
phase II clinical trial suggested a limited, but clear
therapeutic activity of LND in association with radio-
therapy as a first line treatment and in association with
Lomustine (CCNU) at recurrence. The ability to reduce
viability of TZM-resistant cells encourages re-evaluation
of the use of LND in chemotherapy protocols in new
combinations with other cytotoxic and/or antiprolifera-
tive drugs. We were not able to find any published data
about clinical trials including CD437 and BA for
glioblastoma treatment. Our data as well as other
literature [22, 26, 41, 48-51] confirm the antitumor
activity of the novel retinoid and of the white birch tree
extract on high grade astrocytoma cells, encouraging
their use in clinical protocols.
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